August 16, 2018

Researchers find common cell process key to therapy resistance

Ottawa researchers discover a new way to make cancer cells more susceptible to virus-based therapies

Over the past decade, researchers have made significant progress in designing oncolytic viruses (OVs) – viruses that destroy cancer cells while leaving healthy tissue unharmed. However, some cancer cells are resistant to this type of therapy and their resistance mechanisms remain poorly understood.

Researchers at the The Ottawa Hospital and University of Ottawa, under the leadership of Dr. Carolina Ilkow, have discovered that a common cellular mechanism, RNAi, allows cancer cells to fight back against cancer-fighting viruses. Their findings, recently published in the Journal for Immunotherapy of Cancer, show that blocking RNAi processes in tumours can make cancer cells more susceptible to OVs.

Continue reading – Researchers find common cell process key to therapy resistance

May 17, 2018

Combination of erectile dysfunction drugs and flu vaccine may help kill remaining cancer after surgery

A flu vaccine sits on top of packages of erectile dysfunction drugs

A remarkable study led by Dr. Rebecca Auer from The Ottawa Hospital (TOH) shows that the unlikely combination of erectile dysfunction drugs and the flu vaccine may boost the immune system’s ability to clean up cancer cells left behind after surgery. This method demonstrated promising results in a mouse model, where it reduced the spread of cancer following surgery by 90 per cent. Now the approach will be tested in a first-of-its-kind clinical trial involving 24 patients at TOH.

Continue reading – Combination of erectile dysfunction drugs and flu vaccine may help kill remaining cancer after surgery

January 4, 2018

Study shows virus-boosted immunotherapy can be effective against aggressive breast cancer

The Maraba virus is seen under an electron microscope

Researchers at The Ottawa Hospital and the University of Ottawa have found that a combination of two immunotherapies – oncolytic viruses and checkpoint inhibitors – was successful in treating triple-negative breast cancer in mouse models. Triple-negative breast cancer is the most aggressive and hard-to-treat form of the disease.

Continue reading – Study shows virus-boosted immunotherapy can be effective against aggressive breast cancer

July 11, 2017

How OICR is helping to boost the body’s ability to fight cancer

Oncology Viruses - Image of a cell.

The body’s immune system is incredibly powerful. Its ability to detect and destroy various pathogens makes it central to maintaining good health. While we all know the role it plays in fighting the common cold or flu, many do not know that it has recently been enlisted by scientists in the fight against cancer. Researchers in a field known as immuno-oncology are working to find ways to turn on the body’s defences to locate and destroy tumour cells. OICR recently established a team of expert scientists and clinicians to develop and test new immunotherapies to help patients.

Continue reading – How OICR is helping to boost the body’s ability to fight cancer

May 25, 2017

OICR launches five all-star teams of Ontario scientists to tackle some of the deadliest forms of cancer

People from the press conference

Great strides have been made in cancer research, but much work remains to develop better treatments for the most lethal cancers and to advance new anti-cancer technologies. OICR is taking on a new approach, building on the success of the Institute’s first ten years and Ontario’s strength in particular cancer research areas. Reza Moridi, Ontario’s Minister of Research, Innovation and Science announced that the Institute is funding five collaborative, cross-disciplinary and inter-institutional Translational Research Initiatives (TRIs) with a total of $24 million over the next two years.

The TRIs will bring together some of the top cancer researchers in Ontario and be led by internationally renowned Ontario scientists. Each team will focus on a certain type of cancer or therapeutic technology. To maximize the positive impact of research on patients, the TRIs all incorporate clinical trials into their design. The TRIs, which were selected by an International Scientific Review Panel, are:

The funding will also support Early Prostate Cancer Developmental Projects led by Drs. Paul Boutros and George Rodriguez.

“In just over 10 years, the Ontario Institute for Cancer Research has become a global centre of excellence that is moving the province to the forefront of discovery and innovation in cancer research. It is home to outstanding Ontario scientists, who are working together to ease the burden of cancer in our province and around the world,” said Moridi.

“Collaboration and translational research are key to seeing that the innovative technologies being developed in Ontario reach the clinic and help patients,” said Mr. Peter Goodhand, President of OICR. “These TRIs represent a unique and significant opportunity to impact clinical cancer care in the province.”

Read the news release: OICR launches five large-scale Ontario research initiatives to combat some of the most deadly cancers

May 25, 2017

OICR launches five large-scale Ontario research initiatives to combat some of the most deadly cancers

Minister for Research, Innovation and Science

Toronto (May 25, 2017) – Reza Moridi, Ontario’s Minister of Research, Innovation and Science, today announced the Ontario Institute for Cancer Research is launching five unique, cross-disciplinary, multi-institutional Translational Research Initiatives (TRIs), each focused on a single type of or treatment approach to cancer. With $24 million in funding over two years, the TRIs will bring together world-leading scientists to tackle some of the most difficult to treat cancers and test innovative solutions to some of the most serious challenges in cancer today.

The TRIs build on Ontario’s proven strengths in areas such as stem cells, immuno-oncology, pediatric cancers, genomics, clinical trials and informatics. Working together, the province’s top scientists and clinicians will accelerate the development of much needed solutions for patients around the globe, with a focus on acute leukemia and brain, ovarian and pancreatic cancers. Each TRI includes clinical trials to maximize patient impact.

Continue reading – OICR launches five large-scale Ontario research initiatives to combat some of the most deadly cancers